Caplin Point Lab Peer Comparison

NSE: CAPLIPOINT | BSE: 524742

₹2,416.10

₹51.50 (2.18%)

As on 04-Nov-2026IST

Market cap

₹18,365 Cr

Revenue (TTM)

₹2,287 Cr

P/E Ratio

27.6

P/B Ratio

Div. Yield

0.3 %

Edit

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	18,365	18,234	17,532	16,891	15,913
Revenue (₹ Cr)	2,287	1,682	2,654	3,330	2,432
Net Profit (₹ Cr)	678.07	273.51	859.38	720.77	169.62
Net Margin (%)	28.10	16.19	30.42	21.60	6.90
RoE (%)	19.73	11.15	18.58	18.93	20.76
Price to Earnings	27.60	61.33	20.40	23.87	93.81
Price-To-Book	5.00	6.79	3.98	4.08	17.60

Income Statement (₹ Cr)

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	2,287.33	1,682.47	2,654.29	3,329.63	2,432.06
Total Income	2,413.29	1,689.83	2,825.39	3,337.47	2,458.54
Total Expenditure	1,490.75	1,203.91	1,681.39	2,168.88	2,202.20
EBITDA	796.58	478.55	972.90	1,160.75	229.86
Depreciation	78.10	126.01	57.71	285.40	17.24
EBIT	718.48	352.55	915.19	875.35	212.62
Interest	0.88	52.11	8.91	187.51	5.72
Other Income	125.96	7.37	171.10	7.84	26.48
Exceptional Items	0.00	12.16	82.90	-53.14	-5.13
Profit before Tax	843.56	319.96	1,160.28	642.54	228.25
Provision for Tax	165.49	46.45	300.90	-78.23	58.63
Profit after Tax	678.07	273.51	859.38	720.77	169.62

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	3,586.42	2,591.20	4,385.41	4,144.34	872.79
Minority Interest	-12.71	0.00	0.00	-10.85	0.00
Non-Current Liabilities	28.74	266.35	222.21	758.48	134.50
Current Liabilities	385.94	848.06	685.36	2,681.14	981.81
Total Liabilities	4,037.51	3,705.61	4,921.88	7,246.72	2,414.58

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	1,291.22	2,525.44	905.21	5,578.78	42.47
Current Assets	2,585.66	1,109.77	4,024.56	1,800.86	1,739.93
Total Assets	4,037.51	3,705.61	4,921.88	7,246.72	2,414.58
Total Debt*	0.57	657.97	2.50	2,309.68	0.00
Net Current Assets	2,199.72	261.71	3,339.20	-880.28	758.12
Contingent Liabilities	17.53	160.01	370.49	51.57	121.23

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	523.24	342.18	967.57	537.99	-15.14
Cash Flow from Investing Activities	-582.30	-325.92	-561.67	-369.46	18.69
Cash from Financing Activities	-46.46	13.62	-798.31	-313.53	-91.97
Net Cash Inflow / Outflow	-105.52	29.88	-392.41	-145.00	-88.42

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	24.97	11.43	23.39	14.47	31.24
ROE (%)	19.73	11.15	18.58	18.93	20.76
ROA (%)	18.69	7.80	17.36	9.78	9.67
EBIT Margin (%)	31.41	20.95	34.48	26.29	8.74
Net Margin (%)	28.10	16.19	30.42	21.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	15.01	27.91	11.75	11.06	31.10
EBIT Growth (%)	18.45	58.32	21.45	13.71	-12.99
Net Profit Growth (%)	19.61	149.56	2.39	60.98	-7.49
EPS Growth (%)	17.73	-3.57	13.17	80.38	-18.33
Book Value Growth (%)	26.75	9.67	-0.34	36.71	13.51

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	27.60	65.06	21.98	22.11	91.70
Price / Book Value	5.00	6.79	3.98	4.08	17.60
Dividend Yield (%)	0.33	0.06	1.96	0.00	0.57
EV/EBITDA	21.79	39.38	14.83	16.48	67.28
Market Cap (₹ Cr)	11,439.22	6,819.66	21,592.90	17,980.08	19,398.64

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.00	0.07	0.00	0.10	0.00
Short term debt to equity ratio	0.00	0.16	0.00	0.12	--
Current Ratio	6.70	1.31	5.87	0.67	1.77
Quick Ratio	5.59	0.88	5.23	0.49	0.73
Interest Coverage	959.59	7.14	131.22	4.43	40.90

	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	36.10	30.84	9.10	18.98	8.79
Asset Turnover	0.63	0.48	0.54	0.45	1.39
Receivable days	121.68	113.81	26.06	63.88	31.88
Inventory Days	63.83	84.76	65.95	43.27	126.03
Payable days	108.28	101.94	81.01	151.85	163.79
Cash Conversion Cycle	77.23	96.62	11.00	-44.70	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.